- Home
- NEA vs DNLI Comparison
NEA vs DNLI Comparison
Compare NEA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEA | DNLI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NEA | DNLI |
|---|---|---|
| Price | $11.55 | $20.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $34.27 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $444.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.56 | $12.58 |
| 52 Week High | $11.90 | $23.77 |
Technical Indicators
Market Signals| Indicator | NEA | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 52.30 |
| Support Level | $11.46 | $18.86 |
| Resistance Level | $11.77 | $22.21 |
| Average True Range (ATR) | 0.13 | 0.99 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 88.52 | 57.84 |
Price Performance
Historical ComparisonAbout NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.